NexImmune, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 62.51 million compared to USD 50.9 million a year ago. Basic loss per share from continuing operations was USD 65 compared to USD 63.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | +1.91% | +6.31% | +44.14% |
05-20 | NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-17 | North American Morning Briefing : Stock Futures -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+44.14% | 4.39M | |
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+2.71% | 22.82B | |
-9.95% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022